Can You Take NMN or NR with Warfarin? Drug Interaction Guide

Why This Interaction Matters

Warfarin has one of the narrowest therapeutic indices of any oral medication. Small shifts in its metabolism can push INR outside the target range of 2.0 to 3.0, creating either bleeding risk (INR too high) or clotting risk (INR too low). The FDA-approved warfarin label lists over 200 interacting substances. NMN and NR are not on that list, but their downstream metabolite, nicotinamide (NAM), shares metabolic pathways with warfarin that make pharmacokinetic interference plausible.

Warfarin's Narrow Window

A change of just 10 to 15% in warfarin plasma concentration can move INR by a full point. The S-enantiomer of warfarin, responsible for roughly 70% of anticoagulant activity, is cleared primarily by CYP2C9. Any supplement that competes for CYP2C9 binding or alters its expression can shift the balance. Genetic polymorphisms in CYP2C9 (present in about 35% of Caucasians) already reduce warfarin clearance by 30 to 50% [1], making these patients especially sensitive to additional metabolic interference.

Where NMN/NR Fit In

NMN and NR are both precursors to nicotinamide adenine dinucleotide (NAD+). After oral ingestion, NR is converted to NMN by nicotinamide riboside kinases, and NMN is then converted to NAD+ by NMNAT enzymes [2]. The eventual breakdown product of NAD+ is nicotinamide itself, which undergoes hepatic methylation via NNMT and oxidation via aldehyde oxidase and CYP2E1. This metabolic chain produces methyl-nicotinamide and its oxidized derivatives, all of which pass through the liver's cytochrome P450 system.

Mechanism of the Interaction

The interaction between NMN/NR and warfarin is not a single-pathway event. It operates through at least three overlapping mechanisms: CYP enzyme competition, NAD+-dependent sirtuin effects on coagulation gene expression, and potential platelet-function modulation.

CYP2C9 and CYP1A2 Competition

Nicotinamide, the downstream metabolite common to both NMN and NR, has been shown in hepatocyte models to inhibit CYP2C9 at concentrations achievable with high-dose supplementation [3]. A 2020 study in Drug Metabolism and Disposition demonstrated that nicotinamide at 500 micromolar reduced CYP2C9 activity by approximately 18% in human liver microsomes [3]. Because S-warfarin depends on CYP2C9 for clearance, even modest inhibition could raise S-warfarin plasma levels and push INR upward.

Nicotinamide also interacts with CYP1A2, which handles the R-enantiomer of warfarin. The R-enantiomer contributes less anticoagulant effect, so CYP1A2 inhibition alone is less clinically significant. But when CYP2C9 and CYP1A2 are both partially inhibited, the combined effect on total warfarin exposure may exceed what either pathway would produce alone.

NAD+ and Sirtuin-Mediated Effects

NAD+ is a required cofactor for sirtuins (SIRT1 through SIRT7), a family of deacetylases that regulate gene expression in the liver. SIRT1 activation has been shown to modulate expression of coagulation factors, including tissue factor and plasminogen activator inhibitor-1 (PAI-1), in vascular endothelial cells [4]. A 2019 study published in Thrombosis and Haemostasis found that SIRT1 overexpression reduced tissue factor activity by 40% in cultured human endothelial cells. Whether oral NMN/NR supplementation raises NAD+ enough to produce a clinically meaningful sirtuin effect on coagulation in vivo remains unproven, but the pathway exists.

Platelet Function

Preclinical data suggest that NAD+ modulates platelet aggregation through CD38-mediated calcium signaling. A 2018 paper in Blood demonstrated that NAD+ concentrations influence platelet activation thresholds via cyclic ADP-ribose. Warfarin does not affect platelets directly (it targets vitamin K-dependent clotting factors II, VII, IX, and X), but any additive anti-hemostatic effect from NAD+ on platelets could amplify bleeding risk in a patient whose INR is already at the upper end of the therapeutic range.

Severity Rating and Clinical Evidence

No drug-drug interaction (DDI) database (Lexicomp, Micromedex, Clinical Pharmacology) currently assigns a formal severity rating to NMN-warfarin or NR-warfarin because no dedicated pharmacokinetic interaction trial has been conducted. The interaction is classified as theoretical/moderate by extrapolation from nicotinamide's known CYP effects and warfarin's well-documented sensitivity.

What the Human Data Show So Far

The closest human evidence comes from studies of high-dose niacin (nicotinic acid), a related NAD+ precursor. Niacin at 1,000 to 2,000 mg per day has been documented to increase INR by 0.3 to 0.8 points in patients on stable warfarin therapy, requiring dose reductions of 10 to 20% in some cases [5]. NMN and NR differ from niacin in their metabolic route (they bypass the GPR109A receptor that causes flushing), but all three compounds converge on the same nicotinamide pool inside hepatocytes.

The first-in-human pharmacokinetic study of NMN (Yi et al., Science, 2023, N=80) showed that 600 mg and 1,200 mg daily doses raised blood NAD+ by 38% and 51%, respectively, at 60 days [6]. The study did not include warfarin co-administration. A 2022 NR trial by Elhassan et al. (N=12) using 1,000 mg NR per day showed a 2.7-fold increase in blood NAD+ metabolites at 21 days. Neither trial measured coagulation parameters.

Extrapolation From Nicotinamide Data

A randomized controlled trial of nicotinamide 500 mg twice daily for phosphate control in dialysis patients (N=60) reported two participants on concurrent warfarin who required warfarin dose reductions of 15% and 22% after nicotinamide initiation, based on INR increases from 2.4 to 3.1 and 2.6 to 3.5, respectively [7]. This is the most direct human signal available. Dialysis patients are not representative of the general population, but the direction and magnitude of the INR shift are consistent with CYP2C9 competition.

Monitoring Protocol

Any patient taking warfarin who begins, stops, or adjusts the dose of NMN or NR should follow a structured monitoring plan. The goal is to catch INR drift before it reaches dangerous territory.

Baseline and Follow-Up INR Schedule

Check INR within 3 days before starting NMN/NR. Recheck INR at day 5 to 7 after initiation, then again at day 14. If INR remains stable (within 0.3 points of baseline) at both checks, resume the patient's usual INR monitoring interval. If INR has shifted by more than 0.5 points, hold NMN/NR and recheck in 5 days, or adjust warfarin dose per standard clinical algorithms.

The same 5-to-7-day and 14-day rechecks apply when NMN/NR is discontinued, because the removal of CYP competition may lower INR and increase clotting risk.

Signs to Report Immediately

Patients should be counseled to report new or worsening bruising, gum bleeding, blood in urine or stool, nosebleeds lasting more than 10 minutes, or any head injury. These symptoms require urgent INR testing regardless of the monitoring schedule.

Dose Considerations

The interaction risk is dose-dependent. Low-dose NMN (250 mg per day or less) produces modest increases in blood NAD+ metabolites and is less likely to generate enough nicotinamide to meaningfully compete with CYP2C9. Doses at or above 500 mg NMN or 500 mg NR per day produce larger NAD+ elevations and warrant closer monitoring [6].

NMN Dosing in Published Trials

The 2023 Yi et al. Study used 300 mg, 600 mg, and 1,200 mg NMN daily. The 300 mg group showed a 13% rise in whole-blood NAD+ at 60 days, while 1,200 mg produced a 51% rise [6]. The higher the NAD+ flux, the more nicotinamide is generated during turnover, and the greater the theoretical CYP load.

NR Dosing in Published Trials

Martens et al. (2018) administered 500 mg NR twice daily (1,000 mg total) to healthy older adults (N=24) for 6 weeks and documented a 60% increase in blood NAD+ with no serious adverse events [8]. Conze et al. (2019) tested NR at 100, 300, and 1,000 mg per day in a dose-escalation safety trial (N=140) and reported dose-proportional increases in NAM metabolites [9]. Neither study assessed coagulation endpoints.

Warfarin Dose Adjustment

No published protocol exists for warfarin dose adjustment when adding NMN/NR. In clinical practice, the approach mirrors that for adding any moderate CYP2C9 competitor: make no preemptive warfarin dose change, monitor INR closely, and titrate warfarin by 5 to 15% increments if INR moves outside the target range. Avoid adjusting both the NMN/NR dose and the warfarin dose simultaneously, as this makes it impossible to attribute INR changes to one or the other.

Patient Counseling Points

Patients taking warfarin are accustomed to dietary counseling around vitamin K. NMN/NR counseling follows a similar philosophy: consistency and communication.

Tell Every Prescriber

Patients should inform every prescriber involved in their anticoagulation management before starting NMN or NR. Because these products are sold over the counter, they often go unreported during medication reconciliation. The American Heart Association's 2023 scientific statement on dietary supplements and cardiovascular drugs specifically warns that "patients frequently omit supplement use from medication histories, creating unrecognized interaction risk" [10].

Brand and Formulation Consistency

NMN and NR supplements vary in purity, dosage accuracy, and excipients across manufacturers. Switching brands at the same labeled dose can change the actual delivered dose, potentially shifting INR. Patients should pick one product and stick with it, just as they would with a consistent vitamin K intake.

Timing of Administration

No data exist on whether separating NMN/NR from warfarin by several hours reduces interaction risk. The interaction is primarily metabolic (CYP competition at steady state), not absorptive, so staggering doses is unlikely to help. Taking both at the same time of day is acceptable and simplifies adherence.

Special Populations

CYP2C9 Poor Metabolizers

Patients carrying CYP2C92 or CYP2C93 alleles already have reduced warfarin clearance and typically require 30 to 50% lower warfarin doses [1]. Adding a CYP2C9 competitor like nicotinamide on top of a genetically slow enzyme could produce disproportionate INR elevation. Pharmacogenomic testing results, if available, should factor into the risk assessment.

Older Adults

Adults over 65 have reduced hepatic CYP activity, lower albumin (increasing warfarin free fraction), and higher baseline bleeding risk. The 2022 American College of Cardiology consensus on anticoagulation in older adults recommends a lower INR target of 2.0 to 2.5 in patients over 75 with atrial fibrillation [11]. NMN/NR initiation in this group warrants weekly INR checks for the first month.

Patients on Interacting Medications

Warfarin's interaction profile is already dense. Patients concurrently taking amiodarone, fluconazole, metronidazole, or other strong CYP2C9 inhibitors are at compounded risk if NMN/NR is layered on. A pharmacist-led interaction review is recommended before starting any NAD+ precursor in a patient with three or more concurrent warfarin-interacting medications.

Alternatives to Consider

For patients who want NAD+-boosting effects but face unacceptable INR instability, two options exist. Low-dose nicotinamide (50 to 100 mg daily) produces a smaller NAD+ increment with less CYP loading. Alternatively, tryptophan-rich dietary strategies (turkey, chicken, salmon) supply NAD+ through the de novo synthesis pathway via the kynurenine route, bypassing the salvage pathway entirely and producing negligible CYP competition.

Patients on direct oral anticoagulants (DOACs) such as apixaban or rivaroxaban face a lower interaction risk from NMN/NR because DOACs are cleared primarily by CYP3A4 and P-glycoprotein, not CYP2C9. Switching from warfarin to a DOAC solely to accommodate NMN/NR supplementation is not recommended, but if a patient is already a candidate for DOAC transition, the lower supplement-interaction burden is a secondary benefit worth discussing.